^
over1year
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib. (PubMed, Transl Cancer Res)
Last but not least, both pre-clinical and clinical data indicated that dacomitinib has an encouraging intracranial tumor control ability, regardless of uncommon mutations. Dacomitinib demonstrated good disease control on patients with NSCLC harboring major uncommon EGFR mutations and specific EGFR or HER2 mutation subtypes, and selective clinical application of dacomitinib is considerable in this setting, especially for those with intracranial metastases.
Preclinical • Review • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR A763_Y764insFQEA • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L747P • HER-2 M774delinsWLV
|
Vizimpro (dacomitinib)